Why Heartworm-Positive Intake Is a Predictable Operational Problem
In heartworm-endemic regions, an intake-side shelter or rescue can expect a meaningful fraction of incoming dogs to test heartworm-positive. The US Southeast and Gulf Coast, the lower Mississippi Valley, parts of California, Singapore and tropical Asia, the Mediterranean Basin, and parts of South America all show high heartworm prevalence in stray and surrendered dog populations. A workable shelter heartworm-positive intake protocol is essential operational infrastructure for any rescue pulling from these regions or housing dogs that originated in them.
In this article
- Why Heartworm-Positive Intake Is a Predictable Operational Problem
- Testing at Intake
- AHS Class Staging
- The AHS Melarsomine Three-Dose Protocol
- The Slow-Kill Doxycycline-Macrocyclic Protocol
- Cage Rest: The Hard Part
- Foster Placement and Adoption Disclosure
- Cost and Funding Logistics
- Singapore and Tropical Context
- Cats: A Different Disease
- Post-Treatment and the Lifetime Prevention Layer
- Frequently Asked Questions
The American Heartworm Society (AHS) publishes the current canine heartworm guidelines, which serve as the primary reference for treatment-protocol decisions. The Association of Shelter Veterinarians (ASV) integrates AHS guidelines into shelter-context recommendations through UC Davis Koret and University of Florida Maddie’s Shelter Medicine Program materials.
Testing at Intake
Every dog entering the shelter in a heartworm-endemic region is tested at the intake medical exam (see shelter intake medical exam protocol). The point-of-care test is the heartworm antigen SNAP (IDEXX, Antech, or comparable), which detects adult female heartworm antigen. The SNAP is sensitive for established adult infection but does not detect very early infection (the antigen does not appear until adult worms are present, typically six to seven months post-infection).
Positive SNAP results trigger confirmatory testing: microfilaria check via modified Knott’s test or filter test to confirm circulating microfilariae and inform decisions about microfilaricide timing. Heart and lung radiographs assess disease severity (right-heart enlargement, pulmonary artery changes, parenchymal disease). Echocardiography in high-burden cases identifies caval syndrome risk. The heartworm disease in dogs and heartworm in dogs pillars cover the species disease framing; heartworm testing annual covers the testing cadence in adopted dogs.
AHS Class Staging
The AHS guidelines stage canine heartworm disease into four classes by clinical severity, ranging from asymptomatic with minimal radiographic changes (Class 1) to caval syndrome with imminent mortality risk (Class 4). The class determines the treatment approach. Asymptomatic dogs (Class 1 and most Class 2) are candidates for the standard melarsomine three-dose protocol; symptomatic dogs (Class 3) require stabilization before adulticide therapy; caval-syndrome dogs (Class 4) require surgical worm extraction before any adulticide.
Most shelter intake dogs are Class 1 or 2 at diagnosis (asymptomatic or mildly symptomatic). The shelter-medicine veterinarian determines class based on history, exam findings, radiographs, and bloodwork.
The AHS Melarsomine Three-Dose Protocol
The AHS-recommended gold-standard treatment is the melarsomine three-dose protocol. Melarsomine is an organic arsenical adulticide that kills adult heartworms after intramuscular injection. The protocol: one initial injection, then a thirty-day pre-treatment period during which the dog is on cage rest, then two injections twenty-four hours apart at the end of that thirty-day period. The shelter-medicine veterinarian doses by weight and product; this article describes the framework, not numbers.
Pre-treatment doxycycline is the modern adjunct. Wolbachia bacteria live as endosymbionts within heartworms and produce inflammation when worms die. Doxycycline for dogs kills Wolbachia, reducing the inflammatory thromboembolism risk during adulticide treatment. The AHS protocol includes a doxycycline course preceding melarsomine for this reason. Macrocyclic lactone heartworm preventive (ivermectin, milbemycin, moxidectin, or selamectin) is also started before adulticide to suppress microfilariae and prevent new infection during treatment.
The heartworm treatment dogs pillar covers the clinical treatment-protocol detail.
The Slow-Kill Doxycycline-Macrocyclic Protocol
The alternative treatment approach is the “slow-kill” protocol: extended doxycycline plus monthly macrocyclic lactone preventive over many months, without melarsomine. The protocol relies on the antibiotic effect on Wolbachia (which sterilizes adult worms over time) plus the macrocyclic effect on microfilariae and developing larvae. The dog clears the infection over twelve to twenty-four months as adult worms die natural deaths.
The slow-kill approach is operationally attractive in resource-constrained shelters: melarsomine is expensive and requires IM injection, while doxycycline and ivermectin or moxidectin are inexpensive and orally administered. The AHS, however, does not recommend slow-kill as first-line. The argument is that slow-kill prolongs the infection period (continuing parenchymal damage from living worms), increases macrocyclic-lactone resistance pressure on the parasite population, and may not fully clear all worms.
The slow-kill protocol remains in use in shelter contexts where melarsomine is genuinely unavailable or unaffordable, with the shelter-medicine veterinarian making the case-by-case call. Adopter disclosure of the chosen protocol is part of the adoption packet. The controversy is real and honest framing matters; the protocol is documented in peer-reviewed literature but is not the AHS first-line recommendation.
Cage Rest: The Hard Part
The most operationally challenging component of heartworm treatment is the strict cage rest required during and after adulticide therapy. Dying worms release fragments that lodge in pulmonary arteries; physical activity during this period dramatically increases thromboembolism risk and can cause sudden death. AHS protocol mandates strict cage rest from the first melarsomine injection through at least six to eight weeks after the final injection.
In a shelter setting, strict cage rest in an active kennel ward is operationally difficult: the dog can be calm in his run but the surrounding environment is stimulating. Foster placement during the cage-rest period is the operationally superior arrangement: a quiet home with a committed foster who can enforce leash-only bathroom breaks and prevent all running, jumping, and play. This is the operational case for foster networks specifically supporting heartworm-positive intake dogs.
Foster Placement and Adoption Disclosure
Many shelters partner with foster networks for heartworm-positive cases. The foster covers the cage-rest period, administers oral medications, and observes for treatment complications. The foster medical training pillar covers the home-care expectations; a foster taking a heartworm-positive dog needs explicit training on cage rest, signs of thromboembolism (sudden weakness, coughing blood, collapse), and twenty-four-hour vet escalation access.
Adoption can occur during treatment or after completion, depending on shelter policy. Adopter disclosure is comprehensive: which protocol was chosen, where treatment stands, what restrictions still apply, what follow-up testing is needed. The adopting a dog with heartworm and adopting heartworm-positive dog adopter-facing pillars cover the disclosure framework.
Cost and Funding Logistics
Heartworm treatment is expensive. Melarsomine alone costs several hundred to over a thousand dollars per dog depending on weight, and pre-treatment workup (radiographs, bloodwork, doxycycline course) adds to the total. The slow-kill protocol is cheaper but extends over a year.
Funding sources include direct adopter contribution (many adopters of heartworm-positive dogs accept a partial-cost share), shelter foundation grants, Pets For Life-style outreach funding for low-income communities, and partnerships with national rescue funding orgs. Honest budget math at the shelter level determines what is operationally sustainable; some shelters pull only as many heartworm-positive intakes as they can afford to treat in a given cycle.
Singapore and Tropical Context
Singapore and other tropical-Asian rescue environments deal with year-round heartworm pressure. The heartworm prevention Singapore pillar covers the prevention framework. The intake protocol layers heartworm testing onto every dog regardless of origin, because both local dogs and imported rescue dogs from regional countries may be positive at intake. Year-round preventive coverage is the operational standard; gaps of even a single month in tropical climate can result in infection.
Where heartworm-positive dogs are flown internationally for adoption (the long-running US-Asia rescue corridor), treatment may be completed before transport or initiated in the receiving country; clear communication between sending and receiving rescues is operationally essential.
Cats: A Different Disease
Feline heartworm is a different disease operationally and clinically. Cats are not natural heartworm hosts; infection produces fewer worms but with disproportionate inflammatory consequences (heartworm-associated respiratory disease, HARD). There is no AHS-approved adulticide for cats. Treatment is supportive care plus prevention to avoid reinfection. The heartworm disease in cats and cat heartworm pillars cover the cat-side disease.
Shelter cats in heartworm-endemic regions should be on monthly preventive, even indoor-only cats, because mosquito intrusion into homes is documented and the consequences of feline infection are severe.
Post-Treatment and the Lifetime Prevention Layer
After successful treatment, dogs return to normal activity (gradually, over weeks). Annual heartworm testing continues for life because reinfection is possible if preventive lapses. The adoption discharge packet specifies the next testing date and reinforces the year-round preventive expectation.
The adoption discharge packet documents the dog’s heartworm history, the protocol used, the completion status, and the next testing and preventive dates. Continuity of care in the adopter’s primary-care veterinary practice is the operational handoff.
Frequently Asked Questions
Should we use melarsomine or slow-kill?
The American Heartworm Society recommends melarsomine three-dose as the first-line standard. Slow-kill is in use where resources prevent melarsomine; the shelter-medicine veterinarian makes the case-by-case call. Adopter disclosure of the protocol used is part of the adoption packet either way.
What’s the success rate?
Melarsomine three-dose with strict cage rest and AHS adjuncts has a high success rate (most peer-reviewed studies report greater than ninety-five percent clearance). Slow-kill rates are lower and the timeline is longer, but it is a documented protocol in published literature.
Can a heartworm-positive dog be adopted before treatment is complete?
Yes, with comprehensive adopter disclosure, written treatment plan, and continuity with a primary-care veterinarian. Many shelters have adoption-during-treatment programs that pair the dog with a committed adopter who completes the treatment under shelter veterinary guidance.
How long does treatment take?
Melarsomine three-dose total timeline is approximately three to four months from start to clearance testing. Slow-kill is twelve to twenty-four months. Cage rest during treatment is the operational hard part regardless of protocol.
Is treatment safe?
Adulticide treatment carries risk; thromboembolism from dying worms is the primary complication and can be fatal. Strict cage rest, pre-treatment doxycycline, and shelter-medicine-veterinarian-supervised treatment minimize the risk. Most treated dogs complete the protocol without complications when the cage-rest requirement is honored.